A failed trial for a heart drug casts shadow over rivals developing similar therapies

A failed trial for a heart drug casts shadow over rivals developing similar therapies A failed trial for a heart drug casts shadow over rivals developing similar therapies The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels The full clinical-trial data for a heart drug from Ionis and Novartis showed that pelacarsen didn’t reduce the risk of major cardiovascular events. A late-stage clinical-trial failure of Ionis Pharmaceuticals and Novartis’ highly anticipated heart drug is raising questions about whether similar therapies will work. Ionis and Novartis teamed up in 2019 to develop pelacarsen, which Ionis discovered.

But in September, Novartis revealed that the once-monthly injection failed the Phase 3 trial. And over the weekend, a medical journal published detailed findings that showed pelacarsen didn’t lower the risk of major adverse cardiovascular events like heart attacks or strokes after about five years. Novartis will no longer develop the drug, according to Bloomberg. plunged 17.8% in premarket trade on Monday in response to the data and its third-quarter results, which included lowering sales guidance for Tryngolza, another heart drug.

Don’t Short Yourself offers weekly money tips to help you earn it, stack it and grow it. I agree to the Terms of Use, Privacy Notice and Cookie Notice. I would like to receive updates and special offers from Dow Jones and affiliates.

I can unsubscribe at any time. Pelacarsen is an antisense oligonucleotide, which blocks production of certain proteins that can damage the heart. In the “Horizon” trial, the drug reduced lipoprotein(a), which is similar to “bad” cholesterol — except it’s inherited.

Changing your diet or taking a statin doesn’t lower Lp(a). Scientists believed that reducing Lp(a) would lead to a reduction in serious heart events. In 2025, one described targeting Lp(a) as “the next frontier in cardiovascular disease.” But now that the study’s results are out, pelacarsen’s failure raises questions about similar LP(a)-lowering therapies being developed by other drugmakers.

That includes Eli Lilly’s olpasiran, both of which are in Phase 3 studies. Analysts have said they expect olpasiran to generate $2.3 billion in peak sales by 2036. Its closing price was $38.80 on Thursday, down from its year-to-date high of $86.50 on Feb. 6.